Posted on February 4th, 2012 by Health News
In Europe, the number of seniors aged 70 and over will increase by 40% in the next 20 years, while those aged 80 and over will more than double. Health authorities and the medical community expect a corresponding increase in the number of people suffering costly and debilitating age-related chronic diseases such as osteoporosis, arthritis, [...]
No Comments »
Filed under: Pharmacy News
Posted on February 2nd, 2012 by Health News
Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor — used respectively for arthritis pain and lowering cholesterol — shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.
No Comments »
Filed under: Pharmacy News
Posted on January 19th, 2012 by Health News
Medications or biologic agents that target T-cells, white blood cells involved in the body’s immune system, appear to offer significant benefit to patients suffering from psoriatic arthritis (PsA), a type of arthritis that affects up to 48 percent of patients with the skin disease psoriasis, according to a new review article in the Journal of [...]
No Comments »
Filed under: Pharmacy News
Posted on December 26th, 2011 by Health News
A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn’s and rheumatoid arthritis, the immune system mistakenly attacks the body’s tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body’s players in autoimmune processes, an enzyme known as [...]
No Comments »
Filed under: Pharmacy News
Posted on December 21st, 2011 by Health News
UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.
No Comments »
Filed under: Pharmacy News
Posted on December 21st, 2011 by Health News
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
No Comments »
Filed under: Pharmacy News
Posted on December 1st, 2011 by Health News
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS’ journal Biochemistry.
No Comments »
Filed under: Pharmacy News
Posted on November 22nd, 2011 by Health News
Pfizer Inc. announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA).
No Comments »
Filed under: Pharmacy News
Posted on November 12th, 2011 by Health News
Researchers exploring why some women who take a common breast cancer drug develop serious joint pain have eliminated two possible causes: inflammatory arthritis and autoimmune disease.
No Comments »
Filed under: Pharmacy News
Posted on November 7th, 2011 by Health News
Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept, one-third achieved an excellent response, and this response was associated with low measures of disability at study entry, younger age at the onset of JIA, and fewer disease-modifying antirheumatic drugs used before initiating etanercept, according to a study appearing in JAMA.
No Comments »
Filed under: Pharmacy News
